Heptares Adds Two GPCR Partners | Chemical & Engineering News
Volume 93 Issue 48 | p. 27 | Concentrates
Issue Date: December 7, 2015

Heptares Adds Two GPCR Partners

Department: Business
Keywords: pharmaceuticals, biotech, GPCRs, CGRPs

Heptares Therapeutics has struck deals with two companies hoping to tap into its G protein-coupled receptor (GPCR) expertise. Heptares and Pfizer will work together to develop drugs targeting up to 10 GPCRs, with the biotech earning up to $189 million per target. Pfizer will also take a stake worth $33 million in Heptares’s parent company, Sosei. Separately, Teva Pharmaceutical Industries will pay $10 million for the rights to Heptares’s small-molecule antagonists of a GPCR protein called CGRP for the treatment of migraines. Teva says the Heptares molecules will complement its TEV-48125, an anti-CGRP antibody.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment